Screening for NAFLD in primary care: a preventative wonder or are we barking up the wrong tree?
Posted 31st January 2020 by Joshua Sewell
The burden of chronic liver disease has a substantial health and economic burden within the UK. Chronic liver disease is the fifth most common cause of death in the UK and of those five, it is the only one with numbers that are rising. With this in mind, it would make sense that earlier detection of liver disease in primary care is key to improving outcomes and reducing costs.
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Posted 24th May 2019 by Joshua Sewell
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.
Inhibiting NOX enzymes to treat multiple diseases with high medical need
Posted 13th May 2019 by Joshua Sewell
NOX enzymes are a family of enzymes which amplify multiple signalling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.
Stem cell based anti-NASH drug testing: a pragmatic approach for a complex disease
Posted 29th April 2019 by Joshua Sewell
Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.
The Genetics of progressive NAFLD
Posted 24th April 2019 by Joshua Sewell
Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.
A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD
Posted 27th March 2019 by Joshua Sewell
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.
Is Not Dying Yet on your bucket list?
Posted 30th November 2018 by Jane Williams
The Fatty Liver Foundation exists because I was not willing to be a well behaved member of the parade of misery that liver disease is becoming for our society. My bucket list includes not dying of liver disease.
The race to find a treatment for NASH; what’s the big hold up?
Posted 12th June 2018 by Jane Williams
If I were to tell you that there was a multi-million pound race to help more than 1 billion people – you would call me crazy, but believe it or not, it’s actually true! In recognition of International NASH Day, I’m asking what’s the big hold up when it comes to treating NASH?